<DOC>
	<DOCNO>NCT02716272</DOCNO>
	<brief_summary>The sponsor raise hypothesis inhibition immune PD-1+/- CTLA-4 check-point ( ) would delay tumor progression patient unresectable MPM , experience disease progression one two line chemotherapy include least first-line pemetrexed platinum , without alter significantly quality life patient .</brief_summary>
	<brief_title>Nivolumab Monotherapy Nivolumab Plus Ipilimumab , Unresectable Malignant Pleural Mesothelioma ( MPM ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>1 . Histologically proved diagnosis unresectable malignant pleural Mesothelioma ( MPM ) 2 . Available ( archival and/or fresh ) pathological sample centralize PDL1 expression assessment immunohistochemistry 3 . Age ≥ 18 year old ; male female 4 . ECOG Performance status 01 5 . Weight loss &lt; 10 % last 3 month 6 . Life expectancy &gt; 12 week 7 . Documented progression MPM , assess compute tomography ( CT ) Scan . 8 . Measurable disease , define least 1 lesion ( measurable ) accurately assessed baseline CTScan suitable repeat assessment use modify Response Evaluation Criteria Solid Tumors [ RECIST ] pleural mesothelioma ( Byrne 2004 ; Therasse 2006 ) . 9 . Previous treatment 1 2 systemic chemotherapy line ( 1 line chemotherapy consider patient receive ≥2 cycle chemotherapy ) , include least one line pemetrexed combination platinum agent ( i.e . `` gold standard chemotherapy MPM ; triplet include bevacizumab also accept ) 10 . Written inform consent 11 . Patients must adequate organ function : creatinine clearance &gt; 50 mL/min ( Cockcroft formula ) , Neutrophiles count &gt; 1500/mm3 ; Platelets &gt; 100 000/mm3 ; Hemoglobin &gt; 9 g/dL ; hepatic enzyme &lt; 3N total bilirubin ≤ 1.5 × ULN ( upper limit normal ) except subject document Gilbert 's syndrome ( ≤ 5 × ULN ) liver metastasis , must baseline total bilirubin ≤ 3.0 mg/dL 12 . Recovered toxicity associate prior treatment , acceptable baseline status , National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE v4.0 ) Grade 0 1 , except toxicity consider safety risk , alopecia vitiligo 13 . Females childbearing potential sexually active nonsterilized male partner must use highly effective method contraception 28 day prior first dose investigational product , must agree continue use precaution 6 month final dose investigational product ; cessation contraception point discuss responsible physician . Periodic abstinence , rhythm method , withdrawal method acceptable method contraception . They must also refrain egg cell donation 6 month final dose investigational product . Men receive nivolumab sexually active woman childbearing potential instruct adhere contraception period 31 week last dose nivolumab . 1 . Patients primitive peritoneal , pericardial , testis tunica vaginalis mesothelioma 2 . Patients recent history malignancy except adequately treat nonmelanoma skin cancer , curatively treated insitu cancer . Patients prostate adenocarcinoma diagnose less 5 year could include case localize prostate cancer good outcome accord Amico classification : ≤ T2a Gleason Score ≤6 PSA blood level ≤10 ng/ml , treat curative intent ( surgery radiotherapy ) without chemotherapy . Patients history solid tumor , include adenocarcinoma , treat curative intent without evidence disease &gt; 5 year include well . 3 . Brain metastasis , except surgically resect treated stereotaxic radiotherapy evolution within 3 month inclusion , asymptomatic patient 4 . History primary immunodeficiency , history organ transplant require therapeutic immunosuppression use immunosuppressive agent within 28 day randomization prior history severe ( grade 3 4 ) immune mediate toxicity immune therapy . 5 . Subjects condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day randomization . Intranasal/inhaled topical steroid , adrenal replacement steroid dose ≤ 10 mg daily prednisone equivalent , permit absence active autoimmune disease . 6 . Live attenuate vaccination administer within 30 day prior randomization . 7 . Known history interstitial lung disease ( asbestosis… ) CTscan sign interstitial lung disease . 8 . Subjects active , know suspected autoimmune disease , include systemic lupus erythematosis Wegener 's granulomatosis . Subjects type I diabetes mellitis , hypothyroidism require hormone replacement , skin disorder ( vitiligo , psoriasis , alopecia ) require systemic treatment , permit enroll . 9 . Active history inflammatory bowel disease ( eg , diverticulitis , colitis , Crohn 's ) , irritable bowel disease , celiac disease serious gastrointestinal chronic condition associate diarrhea . Note diverticulosis permit . 10 . Patients active uncontrolled infection serious illness medical condition would permit patient manage accord protocol . This include limited : know prior history active tuberculosisdisease ; know acute chronic B C hepatitis serological evaluation . Patients serological sequelae hepatitis ( antibodies test serologically positive virus ) without hepatitis could include . know Human immunodeficiency virus infection . 11 . Prior treatment antiPD1 , antiPDL1 , antiPDL2 , antiCTLA4 antibody , antibody drug specifically target Tcell costimulation checkpoint pathways 12 . The last dose prior chemotherapy radiation therapy ( exception palliative radiotherapy ) receive less 3 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>mesothelioma</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>nivolumab</keyword>
	<keyword>ipilimumab</keyword>
</DOC>